Key result
Flecainide linked to ~67% reduction in exercise-induced PVC frequency in PKP2 arrhythmogenic cardiomyopathy.
Why the study?
Exercise-induced ventricular arrhythmias are common in PKP2-related arrhythmogenic cardiomyopathy, but the effect of flecainide on exercise and recovery-phase arrhythmias is unclear.
Does flecainide reduce exercise-induced arrhythmic burden in patients with PKP2-related arrhythmogenic cardiomyopathy?
Cohort (n=8)
Does flecainide reduce exercise-induced arrhythmic burden in patients with PKP2-related arrhythmogenic cardiomyopathy?
Flecainide effectively suppresses exercise- and recovery-related ventricular ectopy and complex arrhythmias in patients with PKP2-related arrhythmogenic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support flecainide for exercise-related ectopy in PKP2-ACM; hypothesis-generating and requires prospective confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Castrichini et al. (2026) conducted a cohort in PKP2-related arrhythmogenic cardiomyopathy (n=8). Flecainide vs. Off-flecainide (baseline) was evaluated on Premature ventricular contraction (PVC) frequency during exercise (p=0.023). Flecainide significantly reduced premature ventricular contraction frequency during exercise (from 3 to 1 PVCs/min) and recovery (from 12 to 2 PVCs/min) in patients with PKP2-related arrhythmogenic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: